newsroom.csl10d
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III ...
newsroom.csl5d
Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships
Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are ...
newsroom.csl4d
Global Newsroom
MELBOURNE – 24 October 2024 – Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are developing ...
newsroom.csl13d
CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources
SUMMIT, N.J., September 18, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal ...
newsroom.csl1mon
OPTIONS XII IS COMING HOME
As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the second ...